OrbiMed’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

OrbiMed’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-671,000	Closed	-$55.7M	–	149
2017 Q1	$55.7M	Hold	671,000	–	–	0.63%	47
2016 Q4	$53.2M	Sell	671,000 -365,100	-35%	-$26.5M	0.68%	48
2016 Q3	$72.5M	Hold	1,036,100	–	–	0.83%	47
2016 Q2	$40.2M	Buy	+1,036,100	New	+$43.1M	0.42%	57

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

OrbiMed's EGRX Position: Q2 2017 in Review

OrbiMed sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2017, closing a stake of 671,000 shares — an estimated $55.7M sold.

OrbiMed first reported a position in EGRX in Q2 2016 and held it in 4 quarters. The position peaked at $72.5M in Q3 2016. 175 funds tracked by Wall St. Rank hold EGRX as of Q2 2017.

OrbiMed reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
OrbiMed sold 671,000 Eagle Pharmaceuticals, Inc. shares in Q2 2017, an estimated $55.7M.
OrbiMed first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
OrbiMed's Eagle Pharmaceuticals, Inc. position peaked at $72.5M in Q3 2016.
175 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2017.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.